These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Involvement of soluble guanylate cyclase alpha(1) and alpha(2), and SK(Ca) channels in NANC relaxation of mouse distal colon. Dhaese I; Vanneste G; Sips P; Buys E; Brouckaert P; Lefebvre RA Eur J Pharmacol; 2008 Jul; 589(1-3):251-9. PubMed ID: 18572161 [TBL] [Abstract][Full Text] [Related]
50. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles. Sobey CG; Faraci FM Stroke; 1997 Apr; 28(4):837-42; discussion 842-3. PubMed ID: 9099205 [TBL] [Abstract][Full Text] [Related]
51. In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway. Fedele E; Jin Y; Varnier G; Raiteri M Br J Pharmacol; 1996 Oct; 119(3):590-4. PubMed ID: 8894183 [TBL] [Abstract][Full Text] [Related]
52. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate. Hussain AS; Marks GS; Brien JF; Nakatsu K Can J Physiol Pharmacol; 1997 Aug; 75(8):1034-7. PubMed ID: 9360020 [TBL] [Abstract][Full Text] [Related]
53. Intrathecal cGMP elicits pressor responses and maintains mean blood pressure during haemorrhage in anaesthetized rats. Malik V; Holobotovskyy VV; Phillips JK; McKitrick DJ; Arnolda LF J Physiol; 2007 Jun; 581(Pt 2):543-52. PubMed ID: 17347277 [TBL] [Abstract][Full Text] [Related]
54. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. Kruuse C; Rybalkin SD; Khurana TS; Jansen-Olesen I; Olesen J; Edvinsson L Eur J Pharmacol; 2001 May; 420(1):55-65. PubMed ID: 11412839 [TBL] [Abstract][Full Text] [Related]
55. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat. Xia XD; Xu ZJ; Hu XG; Wu CY; Dai YR; Yang L Cell Biochem Funct; 2012 Jun; 30(4):279-85. PubMed ID: 22290599 [TBL] [Abstract][Full Text] [Related]
56. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Olesen SP; Drejer J; Axelsson O; Moldt P; Bang L; Nielsen-Kudsk JE; Busse R; Mülsch A Br J Pharmacol; 1998 Jan; 123(2):299-309. PubMed ID: 9489619 [TBL] [Abstract][Full Text] [Related]
57. Influence of soluble guanylate cyclase inhibition on inflammation and motility disturbances in DSS-induced colitis. Van Crombruggen K; Van Nassauw L; Demetter P; Cuvelier C; Timmermans JP; Lefebvre RA Eur J Pharmacol; 2008 Jan; 579(1-3):337-49. PubMed ID: 18022154 [TBL] [Abstract][Full Text] [Related]
58. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Crassous PA; Couloubaly S; Huang C; Zhou Z; Baskaran P; Kim DD; Papapetropoulos A; Fioramonti X; Durán WN; Beuve A Am J Physiol Heart Circ Physiol; 2012 Sep; 303(5):H597-604. PubMed ID: 22730391 [TBL] [Abstract][Full Text] [Related]
59. Age-dependent modulation of endothelium-dependent vasodilatation by chronic hypoxia in ovine cranial arteries. Williams JM; Pearce WJ J Appl Physiol (1985); 2006 Jan; 100(1):225-32. PubMed ID: 16179402 [TBL] [Abstract][Full Text] [Related]